Accessibility Menu
Nutriband logo

Nutriband(NASDAQ) NTRB

Market Cap$36.22MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2017)-47%
5 Year-57%
1 Year-58%
1 Month-5%
$2.97
+1.36%
+0.04Today
Nutriband last closing stock price
MetricPriceDate
Last closeUSD 2.982026-07-24
Nutriband stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-4.18%USD 3.112026-07-17
1 month-5.1%USD 3.142026-06-24
3 month-25.42%USD 4.002026-04-24
Year to date-34.36%USD 4.542025-12-31
1 year-57.72%USD 7.052025-07-24
3 year-4.73%USD 3.132023-07-25
5 year-56.54%USD 6.862021-07-23
Since inception-47.32%USD 5.662017-11-30

Nutriband Financials at a Glance

Market Cap

$36.22MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$1.80M

Net Income (TTM)

-$8.08M

EPS (TTM)

-$2.63

P/E Ratio

-1.13

Dividend

$0.00

Beta (Volatility)

0.74 (Low)

Price

$2.97

Volume

0

Open

$3.09

Previous Close

$2.97

Daily Range

$2.97 - $3.09

52-Week Range

$2.90 - $8.63

Estimated Earnings Date

Sep 30, 2026

NTRB News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Nutriband

Nutriband makes skin patches that deliver medicine without pills or injections. Its main products help prevent misuse of strong painkillers and treat chronic conditions. These patches aim to make treatment safer and easier for patients and healthcare providers.

Patches, Tapes, and More: What Nutriband Sells

  • Transdermal Patches (100% revenue): Skin patches for drug delivery, mainly for pain and chronic conditions; used by patients needing steady medication.
  • Abuse-Deterrent Systems: Patches designed to prevent misuse of opioids and stimulants; target patients at risk of drug abuse.
  • Contract Manufacturing: For the three and six months ended July 31, 2025, 100% of revenue came from producing health and wellness products for other companies, serving consumer health and over-the-counter markets.
  • Sports Kinesiology Tape: Tape for athletes and physical therapy; supports muscles and joints during activity.
  • Medical Device Licensing: Develops closed system transfer devices to reduce drug exposure risks for healthcare workers.

Growth Spurts and Strategic Moves

  • Partnered with Kindeva Drug Delivery in January 2024 for commercial development of abuse-deterrent fentanyl patches.
  • Expanded AVERSA technology pipeline to include new drug patches in 2024 and 2025.
  • Completed $8.4 million equity financing with European investors in April 2024.
  • Added new manufacturing equipment at Pocono Pharmaceuticals in 2025 to meet rising demand.
  • Signed licensing deal with Rambam Med-Tech for medical device development.

Why Nutriband Catches the Eye

Nutriband focuses on making drug patches safer by adding features that deter misuse. Its dual business model combines steady contract manufacturing with high-risk, high-reward pharmaceutical research. The company’s small size allows for quick shifts in strategy and product focus.

Five Things You Need to Know

  • Revenue was $622,452 in Q2 2025, up 40.6% from Q2 2024.
  • Net loss was $2.0 million in Q2 2025, which represents a 17.3% larger loss year-over-year.
  • All revenue in 2025 came from contract manufacturing, with no pharmaceutical sales yet.
  • Cash and cash equivalents were approximately $7.0 million as of July 31, 2025.

Bottom Line

Nutriband has evolved from a single-product biotech to a dual-focus company. It balances contract manufacturing revenue with investment in innovative drug delivery patches.

AI Generated • Apr 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

13

CEO

Gareth R. Sheridan

Website

www.nutriband.com

Headquarters

Orlando, FL 32801, US

NTRB Financials

Key Financial Metrics (TTM)

Gross Margin

28.35%

Operating Margin

-452.61%

Net Income Margin

-448.39%

Return on Equity

-112.60%

Return on Capital

-120.12%

Return on Assets

-117.27%

Earnings Yield

-88.50%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$36.22MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

12.16M

Volume

0

Avg. Volume

12.28K

Financials (TTM)

Gross Profit

$511.13K

Operating Income

-$8.16M

EBITDA

-$7.89M

Operating Cash Flow

-$4.36M

Capital Expenditure

$5.33K

Free Cash Flow

-$4.36M

Cash & ST Invst.

$4.01M

Total Debt

$232.71K

Nutriband Performance Analysis

Nutriband annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-01-31USD 2,079,60946.2%
20242024-01-31USD 2,085,3140.3%
20252025-01-31USD 2,139,5372.6%
20262026-01-31USD 2,036,651-4.8%
Nutriband sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-07-31-6.7%
Q32025-10-31-44.4%
Q42026-01-3115.8%
Q12026-04-308.2%
Nutriband annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-01-31USD -0.53-34.0%
20242024-01-31USD -0.6930.1%
20252025-01-31USD -0.9943.3%
20262026-01-31USD -2.58161.2%
Nutriband sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-07-31-1666.7%
Q32025-10-3184.9%
Q42026-01-3175.1%
Q12026-04-30-25.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$433.40K

-35.1%

Gross Profit

$196.80K

-21.9%

Gross Margin

45.41%

N/A

Market Cap

$36.22MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.79M

N/A

Employees

13

N/A

Net Income

-$1.24M

+10.6%

EBITDA

-$1.20M

+9.3%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$4.01M

+35.2%

Total Debt

$232.71K

-17.6%

Accounts Receivable

$2.63K

-97.2%

Inventory

$121.49K

-43.6%

Long Term Debt

$70.18K

-43.3%

Short Term Debt

$162.54K

+2.4%

Return on Assets

-1.17%

N/A

Return on Invested Capital

-1.35%

N/A

Free Cash Flow

-$563.10K

+57.9%

Operating Cash Flow

-$563.10K

+57.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
LITSLite Strategy, Inc.
$0.98-1.20%
TCRXTScan Therapeutics, Inc.
$0.77-3.24%
CRVOCervoMed Inc.
$2.66+0.00%
ACRVAcrivon Therapeutics, Inc. Common Stock
$1.56-2.50%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.25+0.10%
NOKNokia
$9.28+0.02%
AALAmerican Airlines Group
$14.95+0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.24-0.02%

Questions About NTRB

What is the current price of Nutriband?

Nutriband is trading at $2.97 per share.

What is the 52-week range for Nutriband?

Over the past 52 weeks, Nutriband has traded between $2.90 and $8.63.

How much debt does Nutriband have?

As of the most recent reporting period, Nutriband reported total debt of $232.71K.

How much cash does Nutriband have on hand?

Nutriband reported $4.01M in cash and cash equivalents in its most recent financial results.

What is Nutriband’s dividend yield?

Nutriband does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services